Highlights
-
19 Apr 2018
- Stable outlook for global pharmaceuticals, but M&A event risk is rising
Our stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas; nonetheless, M&A event risk is rising, reflecting longer-term pressures that will have a growing impact beyond the 12-18 month outlook period. Full Report
-
17 Apr 2018
- Healthcare Quarterly looks at credit impact of planned mergers in US healthcare
Over the past few months, healthcare companies have announced a slew of transactions that continue to blur the lines between traditional healthcare segments and players, with differing credit consequences. Full Report - Listing of lowest-rated corporate issuers down hits three-year low in March
Rating upgrades were the main reason why the list shrank again at the end of the first quarter, despite defaults picking up slightly in February and March. Full Report
|
|
